Journal
VACCINES
Volume 11, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/vaccines11101545
Keywords
gastrointestinal cancer; immunotherapy; cancer vaccines; dendritic cell vaccine; adoptive cell treatment; cytokine-induced killer cells; immune checkpoint inhibitors; angiogenesis inhibition
Categories
Ask authors/readers for more resources
Malignant neoplasms from the GI tract are common and highly fatal. Immunotherapy has limited efficacy in GI cancer, except for a small subgroup. The evaluation of various immunotherapy approaches is ongoing to find more effective treatment options.
Malignant neoplasms arising from the gastrointestinal (GI) tract are among the most common types of cancer with high mortality rates. Despite advances in treatment in a small subgroup harboring targetable mutations, the outcome remains poor, accounting for one in three cancer-related deaths observed globally. As a promising therapeutic option in various tumor types, immunotherapy with immune checkpoint inhibitors has also been evaluated in GI cancer, albeit with limited efficacy except for a small subgroup expressing microsatellite instability. In the quest for more effective treatment options, energetic efforts have been placed to evaluate the role of several immunotherapy approaches comprising of cancer vaccines, adoptive cell therapies and immune checkpoint inhibitors. In this review, we report our experience with a personalized dendritic cell cancer vaccine and cytokine-induced killer cell therapy in three patients with GI cancers and summarize current clinical data on combined immunotherapy strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available